Skye Bioscience Inc
SKYE
NASDAQ
Biotechnology
$0.50
USD
-0.04 (-7.30%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $19.01M
Volume 1.3M
Revenue
$0
TTM
— YoY
Gross Margin
—
TTM
— YoY
Net Income
$-57.33M
TTM
-75.6%
YoY
Operating Cash Flow
$-42.43M
TTM
-42.8%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 |
|---|---|---|---|---|---|
Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
YoY Growth | — | — | — | — | — |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Selling, General & Administrative | 4.6 | 3.9 | 3.9 | 3.4 | 4.7 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 11.8 | 18.2 | 13.3 | 14.9 | 12.7 |
Operating Income | -11.8 | -18.2 | -13.3 | -14.9 | -12.7 |
EBITDA | -11.6 | -18.1 | -13.1 | -14.7 | -12.5 |
Other Income / Expense | 0.0 | 0.1 | 0.1 | 0.2 | -0.0 |
Total Other Income / Expense | 0.7 | 0.6 | 0.5 | 0.5 | 0.2 |
Income Before Income Taxes | -11.1 | -17.6 | -12.8 | -14.4 | -12.5 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | -11.1 | -17.6 | -12.8 | -14.4 | -12.5 |
Consolidated Net Income / Loss | -11.1 | -17.6 | -12.8 | -14.4 | -12.5 |
Net Income Attributable to Common Shareholders | -11.1 | -17.6 | -12.8 | -14.4 | -12.5 |
Basic EPS | -$0.28 | -$0.44 | -$0.32 | -$0.36 | -$0.32 |
Diluted EPS | -$0.28 | -$0.44 | -$0.32 | -$0.36 | -$0.32 |
Basic Shares Outstanding | 39.7M | 39.7M | 39.7M | 39.7M | 39.7M |
Diluted Shares Outstanding | 39.7M | 39.7M | 39.7M | 39.7M | 39.7M |